SAR studies of 6-(arylamino)-4,4-disubstituted-1-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-ones as progesterone receptor antagonists.

[1]  R. Winneker,et al.  Novel 5-aryl-1,3-dihydro-indole-2-thiones. potent, orally active progesterone receptor agonists. , 2003, Bioorganic & medicinal chemistry letters.

[2]  R. Winneker,et al.  Novel 6-aryl-1,4-dihydrobenzo[d]oxazine-2-thiones as potent, selective, and orally active nonsteroidal progesterone receptor agonists. , 2003, Bioorganic & medicinal chemistry letters.

[3]  R. Winneker,et al.  New progesterone receptor antagonists: 3,3-disubstituted-5-aryloxindoles. , 2002, Bioorganic & medicinal chemistry letters.

[4]  R. Winneker,et al.  6-Aryl-1,4-dihydro-benzo[d][1,3]oxazin- 2-ones: a novel class of potent, selective, and orally active nonsteroidal progesterone receptor antagonists. , 2002, Journal of medicinal chemistry.

[5]  Z. Zhang,et al.  Synthesis and progesterone receptor antagonist activities of 6-aryl benzimidazolones and benzothiazolones. , 2001, Bioorganic & medicinal chemistry letters.

[6]  B. Pio,et al.  Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines. , 2000, Bioorganic & medicinal chemistry letters.

[7]  Y. Yamamoto,et al.  Synthesis and structure-activity relationships of new non-steroidal progesterone receptor ligands. , 1999, Bioorganic & medicinal chemistry letters.

[8]  J. Edwards,et al.  Nonsteroidal progesterone receptor antagonists based on a conformationally-restricted subseries of 6-aryl-1,2-dihydro-2,2,4-trimethylquinolines. , 1998, Bioorganic & medicinal chemistry letters.

[9]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[10]  D. Combs,et al.  Nonsteroidal progesterone receptor ligands. 1. 3-Aryl-1-benzoyl-1,4,5,6-tetrahydropyridazines. , 1995, Journal of medicinal chemistry.

[11]  R. N. Brogden,et al.  Mifepristone , 1993, Drugs.

[12]  S. Yen,et al.  Regression of uterine leiomyomata in response to the antiprogesterone RU 486. , 1993, The Journal of clinical endocrinology and metabolism.

[13]  D. Baird,et al.  Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days. , 2002, The Journal of clinical endocrinology and metabolism.

[14]  E. Baulieu,et al.  Treatment of endometriosis with the antiprogesterone mifepristone (RU486) , 1996, Fertility and sterility.